Effect of cariprazine on the 6 domains of schizophrenia in ICD-11: a narrative review

One of the innovations in ICD-11 section "schizophrenia and other primary psychotic disorders" is implementation 6 additional domains, which should improve diagnosis treatment these conditions. Cariprazine a new atypical antipsychotic with predominant affinity for D3 receptors, registered Russia schizophrenia, mania, mixed depressive episodes bipolar I disorder. In modern algorithms schizophrenia dominance negative disorders, pharmacotherapy recommended to start cariprazine, as drug that has best evidence base "negative symptoms" domain. been shown be effective against symptoms "positive domain can considered choice first multiple illness, disorganized thinking disturbed behavior form aggression. The pro-cognitive effect cariprazine proven nonclinical clinical studies, where it developed independently within "cognitive exceeded similar number antipsychotics. use individuals moderate severe "manic may justified view its evidence-based anti-manic efficacy disorder, although does not offer advantages over schizophrenic patients "depressive needs research, since, on one hand, effectiveness comparison placebo relation "depressive" PANSS items, but depression. "psychomotor symptoms", monotherapy well antipsychotics, less justified, since emphasis types therapy.